|
Suprun O.E., Bagriy A.E., Mikhailichenko E.S., Andreeva E.A., Evtushenko A.A., Suprun E.V.
Cohort study of clinical and anamnestic characteristics of patients with a combination of type 2 diabetes mellitus and irritable bowel syndrome
|
№2 / 2024
|
|
S.A. Bulgakov
Selective myotropic antispasmodic mebeverine in functional gastrointestinal disorders
|
№1-2 / 2023
|
|
I.V. Kozlova, T.A. Tikhonova
Irritable bowel syndrome and ulcerative colitis: touch points. Analysis of a clinical case
|
№2 / 2022
|
|
T.S. Krolevets, M.A. Livzan, M.I. Syrovenko
New in the diagnosis and therapy of gluten-associated diseases
|
№2 / 2022
|
|
A.I. Parfenov, O.V. Akhmadullina, E.A. Sabelnikova, L.M. Krums, S.V. Bykova, S.R. Dbar, N.I. Belostotsky, S.G. Khomeriki, E.V. Bystrovskaya
Disaccharidase deficiency under the guise of functional bowel disease
|
№2 / 2019
|
|
N.I. Ursova
Solving the problem of altered microbiocenosis in children with irritable bowel syndrome
|
№1 / 2019
|
|
D.T. Dicheva
WHAT DIFFICULTIES DOES PRACTITIONER FACE IN TREATMENT OF IRRITABLE BOWEL SYNDROME: CLINICAL OBSERVATION
|
№s3 / 2018
|
|
E.V. Borodulina, I.V. Mareyev, M.Yu. Kolokoltsova, I.A. Samykina, V.V. Udut
COMPARATIVE EFFICIENCY OF NEOBUTINE® RETARD, FILM-COATED PROLONGED-RELEASE TABLETS 300 MG, AND TRIMEDAT®, TABLETS 200MG, IN PATIENTS WITH IRRITABLE BOWEL SYNDROME
|
№s5-17 / 2017
|
|
I.A. Oganezova (1, 2), O.I. Medvedeva (1), E.V. Skazyvaeva (1), N.V. Smirnova (2), L.E. Alekseeva (2)
IRRITABLE BOWEL SYNDROME: DIAGNOSIS – “MASK” OF INTESTINAL ABNORMAL DEVELOPMENT
|
№s5-17 / 2017
|
|
I.V. Maev, A.A. Samsonov, A.V. Semenova (Yashina), D.N. Andreev, A.G. Akselrod
NEW APPROACH TO THE PAIN RELIEF IN IRRITABLE BOWEL SYNDROME
|
№6 / 2017
|
|
I.V. Maev, A.A. Samsonov, A.V. Yashina, A.N. Kazyulin, V.A. Shestakov
NEW OPPORTUNITIES IN TREATMENT OF IRRITABLE BOWEL SYNDROME: EFFECTIVE APPROACH AND CORRECTION OF THE QUALITY OF LIFE
|
№15 / 2016
|
|
E.Yu. Plotnikova, T.Yu. Gracheva
ALTERNATIVE THERAPY OF FUNCTIONAL GASTROINTESTINAL DISEASES
|
№2 / 2016
|
Русский
